Esophagitis News and Research

RSS

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

State court jury rules in favor of Merck in FOSAMAX trial

Merck & Co., Inc. today said a state court jury in New Jersey found in its favor in the Rosenberg v. Merck case, rejecting the claims of a woman who blamed her dental and jaw related problems on her FOSAMAX use.

15 Feb 2011

Merck wins third FOSAMAX bellwether trial

Merck & Co., Inc. today said a federal court jury in New York found in its favor in the Graves v. Merck case, rejecting the claims of a Florida woman who blamed her dental and jaw related problems on her FOSAMAX use. With today's verdict, Merck has won three of the first four bellwether cases in the FOSAMAX litigation.

20 Nov 2010

Results of RE-LY trial evaluating Pradaxa capsules to be presented at American Heart Association Session

Results of two pre-specified sub-study analyses of the 18,113 patient RE-LY trial, involving the newly approved oral anticoagulant Pradaxa (dabigatran etexilate mesylate) capsules, will be presented at the American Heart Association's Annual Scientific Sessions on Monday, November 15, 2010.

12 Nov 2010

Boehringer Ingelheim announces availability of PRADAXA in U.S. pharmacies

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that its new oral anticoagulant, Pradaxa® (dabigatran etexilate mesylate) 150mg capsules, will be available starting Wednesday by prescription in pharmacies across the United States, including CVS/pharmacy, Rite Aid, Walmart, Target, Kmart® and The Kroger Co. In addition, leading independents under the Health Mart®, Good Neighbor Pharmacy® and Medicine Shoppe® banners will be stocked.

2 Nov 2010

Fast Neutron Radiotherapy safe and effective for treatment of non-small cell lung cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine (WSU SOM) in Detroit are presenting two research studies that found the use of Fast Neutron Radiotherapy (FNRT) – a form of radiation that is about three times more powerful than typical photon radiotherapy – is highly effective and safe for patients who are dealing with non-small cell lung cancer. The findings are being formally presented Monday, Nov. 1, at the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.

29 Oct 2010

Calypso Medical initiates clinical study to evaluate tracking technology for lung tumors

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumors, today announced the initiation of the first clinical study to evaluate the use of the Calypso System for tracking lung cancer tumors during radiation delivery, including a new design of the Company's implantable Beacon transponder.

28 Oct 2010

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

The U.S. Food and Drug Administration (FDA) has approved Pradaxa (dabigatran etexilate) capsules to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AFib).

20 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Fluticasone gets rid of eosinophils in the esophagus, but does not improve symptoms

A group of Mayo Clinic researchers conducted the first controlled trial of swallowed fluticasone nasal spray (also known as Flonase) on people with the allergic esophageal condition called eosinophilic esophagitis. Research showed that the aerosolized swallowed allergy drug helped treat the cause of the throat condition, but symptoms lingered. The researchers' findings were presented today at the Annual Scientific Meeting of the American College of Gastroenterology in San Antonio.

18 Oct 2010

Caris Life Sciences presents new diagnostic data at ACG 2010

Caris Life Sciences, Inc., a leading biosciences company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic technologies, today announced upcoming highlights from the Company's presentations at the 2010 Annual Meeting of the American College of Gastroenterology ("ACG 2010") held in San Antonio, TX, October 15-20. In total, Caris was awarded 17 accepted abstracts, three of which are ACG Presidential Poster Award recipients.

15 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Mount Sinai receives grant from NIH to continue research on food allergy

Mount Sinai School of Medicine today announced that the National Institutes of Health (NIH) has renewed its funding of the Consortium of Food Allergy Research (CoFAR), providing an additional $29.9 million toward genetic research and the prevention and treatment of food allergy. Mount Sinai is the primary research site for CoFAR, leading seven other institutions around the country.

13 Aug 2010

Study reveals no evidence of link between bisphosphonates to esophageal cancer risk

Although some reports have suggested a link between the use of oral bisphosphonates (drugs that prevent the loss of bone mass) and esophageal cancer, analysis of medical data from more than 80,000 patients in the United Kingdom found that use of these drugs was not significantly associated with new cases of esophageal or gastric cancer, according to a study in the August 11 issue of JAMA.

11 Aug 2010

NIH announces 5 more years of funding for Consortium of Food Allergy Research

Today, the National Institutes of Health announce that the Consortium of Food Allergy Research (CoFAR), established in 2005, will be funded for five more years. CoFAR will continue to foster new approaches to prevent and treat food allergies and also expand in scope to include research on the genetic causes underlying food allergy and studies of food allergy-associated eosinophilic gastrointestinal diseases (EGIDs).

15 Jul 2010

Mutations in Siglec-8 gene may play role in asthma: Research

A gene that encodes a protein responsible for determining whether certain immune cells live or die shows subtle differences in some people with asthma, a team led by Johns Hopkins researchers reports in the June European Journal of Human Genetics.

1 Jul 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Updated phase II study results of OPAXIO in patients with advanced esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO (paclitaxel poliglumex) in patients with advanced esophageal cancer demonstrated that 38% (15/40) patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

7 Jun 2010

RayBiotech announces biomarker grant winners

RayBiotech, Inc. has announced the winners of its Biomarker Discovery Pilot Grant program. In total, 18 award recipients were chosen for grants of up to $20,000 each, redeemable for RayBiotech products and services. "By offering these grants," states Dr. Ray (Ruopan) Huang, Founder and President of RayBiotech, "we intend to demonstrate that any researcher with a modest research budget can successfully discover and validate disease-related biomarkers using our antibody arrays."

6 May 2010

New pathology test may help doctors distinguish between two overlapping esophageal disorders: Study

A pathology test may help doctors distinguish between two separate but overlapping esophageal disorders that require different courses of treatment, according to a study by researchers at the University of North Carolina at Chapel Hill.

5 May 2010